Insulet

OverviewSuggest Edit

Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

TypePublic
Founded2000
HQActon, USMap
Websiteinsulet.com
View Jobs (156)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)1,169(+37%)
Job Openings156
Revenue (FY, 2018)$563.8 M(+22%)
Share Price (Jan 2020)$191 (+2%)

Key People/Management at Insulet

Patrick Sullivan

Patrick Sullivan

Chairman of the Board and Chief Executive Officer
Aiman Abdel-Malek

Aiman Abdel-Malek

Senior Vice President, Advanced Technology and Engineering
Bret Christensen

Bret Christensen

Senior Vice President and Chief Commercial Officer
David Colleran

David Colleran

Senior Vice President, Secretary and General Counsel
Deborah Gordon

Deborah Gordon

Vice President, Investor Relations and Corporate Communications
Michael Levitz

Michael Levitz

Senior Vice President, Chief Financial Officer and Treasurer
Show more

Insulet Office Locations

Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 13 other locations
Acton, US (HQ)
100 Nagog Park
Billerica, US
600 Technology Park Dr #200
Charlotte, US
Charlotte, NC, USA
Chicago, US
Chicago, IL, USA
Columbus, US
Columbus, OH, USA
Denver, US
Denver, CO, USA
Show all (17)

Insulet Financials and Metrics

Insulet Revenue

Embed Graph
View revenue for all periods
Insulet's revenue was reported to be $563.82 m in FY, 2018
USD

Revenue (Q3, 2019)

192.1m

Gross profit (Q3, 2019)

123.1m

Gross profit margin (Q3, 2019), %

64.1%

Net income (Q3, 2019)

852.0k

EBIT (Q3, 2019)

17.0m

Market capitalization (21-Jan-2020)

11.7b

Closing stock price (21-Jan-2020)

191.0

Cash (30-Sept-2019)

419.9m

EV

12.2b
Insulet's current market capitalization is $11.7 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

152.3m211.4m247.1m288.7m324.2m367.0m463.8m563.8m

Revenue growth, %

17%12%13%

Cost of goods sold

85.5m119.0m134.7m145.4m176.1m155.9m186.6m193.7m

Gross profit

66.7m92.3m112.4m143.3m148.2m211.1m277.2m370.2m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

32.2m44.6m47.8m51.0m54.8m57.4m60.1m61.1m69.2m72.0m75.0m61.2m75.6m87.3m81.2m87.3m94.9m101.7m109.8m121.8m123.6m124.3m151.1m159.6m177.1m192.1m

Cost of goods sold

17.7m26.0m27.5m28.7m30.4m32.2m33.3m33.7m36.4m36.2m36.9m28.4m41.2m51.7m37.2m36.9m39.2m42.3m45.1m48.2m47.8m42.2m49.1m52.9m60.7m69.0m

Gross profit

14.5m18.6m20.3m22.3m24.4m25.2m26.8m27.4m32.8m35.8m38.0m32.8m34.4m35.7m44.1m50.5m55.6m59.4m64.6m73.6m75.8m82.1m102.0m106.7m116.4m123.1m

Gross profit Margin, %

45%42%43%44%45%44%45%45%47%50%51%54%45%41%54%58%59%58%59%60%61%66%67%67%66%64%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

94.0m57.3m149.7m151.2m122.7m137.2m272.6m113.9m

Accounts Receivable

23.2m33.3m33.1m39.9m48.4m28.8m53.4m63.3m

Prepaid Expenses

3.7m4.5m5.9m4.0m5.7m9.9m24.3m

Inventories

11.8m14.9m9.5m13.1m14.0m35.5m33.8m71.4m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

106.7m103.8m83.0m70.1m63.4m148.1m150.9m153.9m145.6m175.5m146.4m145.6m145.1m145.5m111.6m75.7m215.4m76.0m73.5m102.2m203.1m136.2m126.6m129.3m119.9m419.9m

Accounts Receivable

20.4m17.3m26.2m25.6m30.1m31.1m33.7m34.5m36.7m41.8m47.1m36.1m31.8m31.8m40.5m38.7m38.5m40.6m37.8m47.2m50.4m49.7m70.0m68.7m67.0m65.1m

Prepaid Expenses

4.8m3.7m3.5m4.3m5.6m6.4m6.6m5.9m7.1m5.7m3.4m3.7m3.4m4.0m5.7m6.8m7.9m8.2m8.4m8.0m17.4m17.6m17.9m28.0m25.2m20.7m

Inventories

16.0m13.1m14.7m16.4m15.1m9.2m6.0m5.4m10.4m8.8m9.7m20.1m23.4m13.0m14.0m24.5m32.7m34.3m34.0m35.1m26.3m40.8m58.1m73.8m85.1m90.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(45.8m)(51.9m)(45.0m)(51.5m)(73.5m)(28.9m)(26.8m)3.3m

Depreciation and Amortization

8.5m11.0m11.8m12.2m15.8m13.8m15.1m15.6m

Inventories

1.9m(3.0m)5.4m(3.6m)(722.0k)(24.1m)1.7m(38.8m)

Cash From Operating Activities

(25.5m)(29.1m)3.3m8.9m(12.6m)15.9m41.2m35.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(29.3m)(42.8m)(14.8m)(29.3m)(41.7m)(10.7m)(21.2m)(42.5m)(6.1m)(35.3m)(46.1m)(11.8m)(27.3m)(46.2m)(12.5m)(16.7m)(19.8m)(10.0m)(17.7m)(20.0m)(6.6m)(8.3m)(6.6m)4.4m5.8m6.6m

Depreciation and Amortization

2.8m5.7m2.8m5.5m8.1m2.9m5.8m8.9m3.1m6.1m9.2m3.4m7.1m11.4m3.4m6.8m10.5m3.3m6.7m10.5m3.5m7.9m11.3m5.1m11.0m18.8m

Inventories

(2.2m)594.0k(2.9m)(4.6m)(3.3m)5.7m8.9m9.5m(985.0k)699.0k(198.0k)(7.0m)(10.3m)312.0k(2.6m)(13.1m)(21.3m)1.2m1.5m428.0k6.7m(8.0m)(25.3m)(2.7m)(14.0m)(20.0m)

Accounts Payable

2.2m1.9m
show all
USDY, 2019

EV/EBIT

719.6 x

EV/CFO

237.7 x

Financial Leverage

8.4 x
Show all financial metrics

Insulet Operating Metrics

FY, 2016

Patents Issued

23

Patents Pending

32
Show all operating metrics

Insulet Revenue Breakdown

Embed Graph

Insulet revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

Insulet Online and Social Media Presence

Insulet's Trends

Embed Graph

Insulet News and Updates

November 25, 2019

lobal Artificial Pancreas Systems Market Report 2019 Top Key Players- Medtronic, Johnson and Johnson, Dexcom, Insulet, Tandem Diabetes Care and more...

A new market study, titled “Global Artificial Pancreas Systems Market Report 2019 - Market Size, Share, Price, Trend and Forecast”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 20, 2019

Why Is Insulet Stock Up More Than 15% Over The Last Month?

Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger...
December 24, 2018

Medication Telemanagement Devices Market 2018 Global Analysis By Key Players – Abiogenix, Adherium, IA Collaborative, Insulet, MedFolio

Wiseguyreports.Com adds “Medication Telemanagement Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 12, 2018

Wearable Medical Equipment Market to witness astonishing growth with Key Players Abbott Diabetes Care, Flextronics International, Insulet Corporation

HTF MI recently launched the Global Wearable Medical Equipment study with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. Posted via Industry Today. Follow us on Twitter @IndustryToday

 Insulet Frequently Asked Questions

  • When was Insulet founded?

    Insulet was founded in 2000.

  • Who are Insulet key executives?

    Insulet's key executives are Patrick Sullivan, Aiman Abdel-Malek and Bret Christensen.

  • How many employees does Insulet have?

    Insulet has 1,169 employees.

  • What is Insulet revenue?

    Latest Insulet annual revenue is $563.8 m.

  • What is Insulet revenue per employee?

    Latest Insulet revenue per employee is $482.3 k.

  • Who are Insulet competitors?

    Competitors of Insulet include Tandem Diabetes Care, POPS! Diabetes Care and LifeScan.

  • Where is Insulet headquarters?

    Insulet headquarters is located at 100 Nagog Park, Acton.

  • Where are Insulet offices?

    Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 13 other locations.

  • How many offices does Insulet have?

    Insulet has 17 offices.